IMCAS 2024: Galderma to present latest updates from its unparalleled aesthetics portfolio reinforcing its leadership position Press release
Galderma announces regulatory approval for Restylane® SHAYPE™, a new hyaluronic acid injectable designed for augmenting the chin region Press release
TOXINS 2024: Galderma’s phase III RelabotulinumtoxinA results demonstrate positive efficacy and long duration of effect when treating frown lines and crow’s feet simultaneously Press release
Results from Galderma’s phase IIIb trials demonstrate rapid and long-lasting effect of RelabotulinumtoxinA on crow’s feet and frown lines Press release
Galderma reports record net sales of over 3 B USD for the first nine months of 2023 with strong growth momentum across all product categories Press release
Galderma phase III data published in The New England Journal of Medicine: full Olympia 2 trial results demonstrate nemolizumab’s rapid onset of action in patients with prurigo nodularis Press release
Galderma @ EADV 2023: phase III trials demonstrate nemolizumab’s efficacy and rapid onset of action in atopic dermatitis and prurigo nodularis Press release
EADV 2023: Galderma to present new data showcasing its continued leadership in dermatology Press release
